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We describe B-cell linear epitopes detected by Pepscan in the Nsp2 and all of the structural proteins of a US PRRSV strain, using sera of 15
experimentally infected pigs. The Nsp2 was found to contain the highest frequency of immunodominant epitopes (n = 18) when compared to
structural proteins. Ten of these 18 Nsp2 peptides were reactive with 80 to 100% of the examined sera. In the structural proteins, epitopes
consistently recognized by immune sera were located at gp2 (n = 2), gp3 (n = 4), gp5 (n = 3), M (n = 2) and N (n = 2). Overall, the highest degree
of immunogenicity and conservation was exhibited by two epitopes identified in the C-terminal end of the M protein (ORF6). The antibodies
recognizing the immunodominant epitopes of each protein were detected as early as days 7 to 15 pi and remained detectable until the end of the
experiment (day 90 pi). These findings have direct implications for PRRSV differential diagnostics and eventual eradication as the identified
epitopes may represent serologic marker candidates for differential (DIVA) PRRSV vaccines, derived from infectious cDNA clones.
© 2006 Elsevier Inc. All rights reserved.Keywords: PRRSV; B-cell epitopes; Peptides; Infectious cDNA clone, PepscanIntroduction
Porcine reproductive and respiratory syndrome (PRRS) is
considered to be one of the most economically important
infectious diseases of swine causing late-term reproductive
failure in pregnant sows and severe pneumonia in neonatal pigs
(Snijder and Meulenberg, 2001). The disease was first reported
in 1989, and the causative agent was isolated and characterized
for the first time in Europe in 1991 and 1 year later in the United
States (Collins et al., 1992).
PRRSV, the etiological agent of PRRS, is an enveloped
single-stranded RNA virus belonging to the order Nidovirales,
family Arteriviridae (Snijder and Meulenberg, 2001). Other
members of Arteriviridae are lactate-dehydrogenase-elevating
virus of mice (LDEV), equine arteritis virus (EAV) and simian
hemorrhagic fever virus (SHFV) (Snijder and Meulenberg,⁎ Corresponding author. Fax: +1 402 472 9690.
E-mail address: fosorio@unl.edu (F.A. Osorio).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.05.0362001). The PRRSV genome is approximately 15 kb in length
and contains eight open reading frames (ORFs). ORFs 1a and 1b
comprise 80% of the genome size and encode a polyprotein
which is co- and post-translationally processed by autoproteo-
lytic cleavage into 12 nonstructural polypeptides (Nsps). The
other six ORFs (2 to 7) are translated into structural proteins
(gp2, gp3, gp4, gp5,M andN). An additional protein encoded by
ORF2b has also been recently characterized (Lee and Yoo, 2005;
Wu et al., 2001).
Significant antigenic and genetic differences have been
reported among North American and European strains of
PRRSV (Allende et al., 1999; Wensvoort et al., 1992). Such
diversities have led to the recognition of two distinct serotypes
of PRRSV: European (type 1) and North American (type 2).
However, the origin of PRRSV remains unknown especially
since the European and North American PRRSV isolates cause
similar clinical symptoms but represent two distinct viral
genotypes with genomic divergences of approximately 40%
(Nelsen et al., 1999).
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since 1995 in the US. The most commonly used vaccine is a
modified-live virus, consisting of a wt PRRSV US strain
attenuated by multiple passages in cell cultures. The efficacy of
these attenuated vaccines currently in use is somewhat disputed
and is generally acknowledged that significant latitude still
exists for technical improvements on their safety and efficacy.
One technical improvement which is central to the effective
implementation of these PRRSV vaccines is endowing them
with differential capability to make them compatible with
elimination of the wt PRRSV infection from a herd. The
serological differentiation between vaccinated and naturally
infected animals has proved crucial for the success of eradication
programs of important livestock diseases (van Oirschot, 1999).
Marker vaccines (also termed DIVA—Differentiating
Infected from Vaccinated individuals) carry at least one
antigenic protein less than the corresponding wild-type virus,
i.e. has a “negative marker” (van Oirschot, 1999), which allows
the serological tracing of wt strains (which obviously are
“marker positive” instead) in vaccinated herds. Classical
examples of modified-live vaccines carrying deletions of non-
essential and immunogenic structural proteins have been
produced for large DNA viruses such as pseudorabies virus
(PRV) and bovine herpesvirus-1 (BHV-1) (Kaashoek et al.,
1994; Moormann et al., 1990; van Oirschot, 1999). These first
successful approaches to DIVAvaccines based on deletion of an
entire glycoprotein from veterinary herpesvirus contributed to
define two fundamental properties of an ideal serologic marker
antigen: 1. the marker candidate has to be immunodominant and
therefore recognized by the vast majority of a population
infected with wt virus; 2. their deletion from the vaccine genetic
make up would not alter the viability and/or protective
immunogenicity of this vaccine. However, the applicability of
such approach for small RNA viruses like PRRSV, which
encode only a few proteins with essential functions, seems
difficult (Welch et al., 2004; Wissink et al., 2005; Yoo et al.,
2004). Therefore, one alternative to be considered for the
selection of negative serological markers for RNA viruses
would be the identification of immunogenic non-essential
epitopes in viral proteins. The approach of epitope deletion has
proved feasible for arteriviruses through deletion of a 46 amino
acid immunodominant region from the ectodomain of the
glycoprotein L (gL) of EAV without deleterious effects on the
replication and immunogenicity of the virus (Castillo-Olivares
et al., 2003). Furthermore, a peptide ELISA based on this
particular domain enabled serological discrimination between
vaccinated and wild-type virus-infected animals.
The presence of B-cell epitopes in nonstructural (mainly
Nsp2) and structural proteins of an EU-type PRRSV strain
have been previously demonstrated by using phage display
libraries (Oleksiewicz et al., 2001, 2002). A few additional
epitopes identified by means of PRRSV N monoclonal
antibodies (Mabs) have also been reported (Meulenberg et
al., 1998; Zhou et al., 2005). Nonetheless, data regarding
functional epitopes on US-type PRRSV-encoded proteins are
scarce. Likewise, there are no available data about immuno-
dominant and conserved B-cell epitopes consistently recog-nized by the humoral immune response of US-type PRRSV-
infected animals. This study reports a detailed and systematic
investigation by Pepscan technology of the US-type PRRSV
B-cell linear epitopes recognized by the convalescent sera
from PRRSV-infected pigs. Our results identify several
immunodominant epitopes within the Nsp2 as well as the
structural proteins of PRRSV.
Results and discussion
Experimental inoculation
Inoculation of fifteen piglets with 105.0 TCID50 of a PRRS
virus recovered from a NVSL 97-7895 strain full-length cDNA
infectious clone by intranasal and intramuscular routes resulted
in a slight increase in rectal temperature (≤1.5 °C) between days
2 and 6 post-infection (pi). Viremia titers ranging from 103.7 to
105.1 TCID50/ml of serum were observed at 7 dpi in all infected
animals indicating active viral replication (data not shown).
Two serum samples collected at 7 dpi and all samples collected
at days 15, 30, 45, 60 and 90 pi were positive for PRRSV-
specific antibodies as assayed by a commercially available
ELISA kit (Idexx Labs, Inc) (data not shown). The results of
virus isolation from blood and ensuing positive serology
demonstrated that productive virus replication and induction
of a normal humoral response took place in all the experimen-
tally infected piglets. Eight of the piglets were euthanized at
60 dpi, and the remaining animals (n = 7) were monitored
serologically until day 90 pi.
Identification of US-type PRRSV-specific linear B-cell epitopes
For the identification of US-type PRRSV-specific B-cell
linear epitopes, convalescent sera (60 dpi) collected from
experimentally infected piglets were used for screening of the
peptide-specific immune response against Nsp2 and all
structural proteins. The serum samples were examined for
antibodies that recognize synthetic peptides used individually as
antigen in a peptide-based indirect ELISA as described in
Materials and methods. The 213 synthetic peptides were
designed based on the amino acid sequence of the North
American strain of PRRSV NVSL 97-7895 (GenBank acces-
sion no. AY545985). Peptide scanning (Pepscan) for epitope
mapping has become increasingly recognized as a method for
identification of diagnostically relevant epitopes within viral
proteins (He et al., 2004a, 2004b; Hohlich et al., 2003;
Khudyakov et al., 1999; Lundkvist et al., 1995; Niikura et al.,
2003).
We identified several B-cell linear epitopes along the amino
acid sequence of all the studied proteins. The identity and
location of the immunodominant epitopes identified in each
protein are presented in Fig. 1 and in Table 1. In general, the
antibodies recognizing the immunodominant epitopes appeared
between day 7 and 15 pi, increased in titer with time and
remained at fairly steady levels up to day 60 pi (Fig. 2).
Nevertheless, the antibody response to the individual epitopes
varied greatly among individual pigs as measured by the optical
Table 1
Immunodominant B-cell linear epitopes identified on Nsp2 and structural
proteins of a North American strain of PRRSV
Peptide no./
protein
Amino acid sequence Position aa a No. of
reactive sera b
3/Nsp2 ALPAREIQQAKKHED 21–35 10/15
4/Nsp2 KKHEDAGADKAVHLR 31–45 8/15
15/Nsp2 ECVQGCCEHKSGLGP 141–155 14/15
24/Nsp2 LCQVVEECCCHQNKT 231–245 14/15
44/Nsp2 PPPPPRVQPRKTKSV 431–445 14/15
45/Nsp2 KTKSVKSLPGNKPVP 441–455 15/15
48/Nsp2 PDGREDLTVGGPLDL 476–490 8/15
50/Nsp2 PMTPLSEPALMPALQ 496–510 10/15
54/Nsp2 VTPLSEPIFVSAPRH 536–550 10/15
55/Nsp2 SAPRHKFQQVEEANL 546–560 14/15
58/Nsp2 ASSQTEYEASPLTPL 576–590 9/15
59/Nsp2 PLTPLQNMGILEVGG 586–600 10/15
61/Nsp2 VLSEISDTLNDINPA 606–620 13/15
76/Nsp2 VPRILGKIENAGEMP 756–770 12/15
79/Nsp2 QPVKDSWMSSRGFDE 786–800 15/15
81/Nsp2 SAGTGGADLPTDLPP 806–820 15/15
82/Nsp2 TDLPPSDGLDADEWG 816–830 10/15
83/Nsp2 ADEWGPLRTVRKKAE 826–840 9/15
102/ORF2 LPSLAGWWSSASDWF 41–55 9/15
110/ORF2 KAGQAAWKQVVSEAT 121–135 9/15
129/ORF3 QAAAEVYEPGRSLWC 61–75 13/15
130/ORF3 RSLWCRIGHDRCSED 71–85 14/15
131/ORF3 RCSEDDHDDLGFMVP 81–95 15/15
132/ORF3 GFMVPPGLSSEGHLT 91–105 15/15
153/ORF4 SCLRHGDSSSQTIRK 51–65 5/15
165/ORF5 MLGRCLTAGCCSRLL 1–15 7/15
168/ORF5 ANSNSSSHLQLIYNL 31–45 8/15
184/ORF5 TPLTRVSAEQWGRL 187–200 13/15
200/ORF6 LKSLVLGGRKAVKQG 151–165 15/15
201/ORF6 AVKQGVVNLVKYAK 161–174 15/15
203/ORF7 KKRGNGQPVNQLCQM 11–25 14/15
206/ORF7 PGKKIKNKNPEKPHF 41–55 7/15
The sequence of the immunoreactive synthetic peptides and the number of
seropositive animals are indicated.
a Localization of the peptide within the amino acid sequence of the respective
ORF.
b Number of reactive sera in the peptide ELISA. The reactivity of 15 sera was
examined against each peptide.
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serum samples available at 90 dpi were also reactive against the
immunodominant epitopes identified (data not shown).
B-cell linear epitopes are scattered along the Nsp2 amino acid
sequence
The Nsp2 protein has been shown to be highly variable
among arteriviruses, with similarities observed only in the
amino- and carboxy-terminal domains whereas the central
region of the protein varies in both length and amino acid
composition (Allende et al., 1999). Interestingly, the Nsp2 was
found to contain the highest frequency of immunogenic
epitopes when compared to the structural proteins examined
in this study. Among the 97 peptides spanning the entire amino
acid sequence of Nsp2, 18 were found to be immunoreactive
with more than 50% of the sera tested. Ten of these peptides
were reactive with 80–100% of the sera examined (Table 1; Fig.
4A). Furthermore, the identified immunodominant B-cell
epitopes were scattered along the protein sequence, and most
of them were localized within predicted hydrophilic regions of
the protein (Fig. 4B). These results were not unexpected since
hydrophilic amino acid sequences are likely exposed on the
surface of the protein and thus may be more easily recognized
by B-lymphocytes. In addition, several other peptides were
recognized by fewer serum samples. No antigenic reactivity was
found within the region comprising peptides #84 and 97 located
in the C-terminal end of the protein (Fig. 4). The lack of
reactivity of peptides spanning this region might be attributed to
the high level of conservation and hydrophobicity of this
segment. A previous report has also demonstrated the
occurrence of a cluster of B-cell epitopes in Nsp2 of an EU-
type PRRSV isolate, 111/92 (Oleksiewicz et al., 2001).
However, the six epitopes identified in that study were not
recognized by antibodies from animals infected with US-type
PRRSV, and no comparison could then be drawn with the
findings of our experiment. In addition, the systematic Pepscan
methodology used in our study allowed the identification of a
higher number of B-cell epitopes in Nsp2 when compared to
those reported for the European strain of PRRSV studies by
phage display technology.
B-cell linear epitopes in the ORF2 protein
The 29–30 kDa glycoprotein 2 (gp2) and the glycoprotein 4
(gp4) are minor components of the PRRSV envelope (SnijderFig. 1. Position of the immunodominant B-cell linear epitopes identified on the Nsp2
identity number of the major synthetic peptides identified as B-cell epitopes in each
epitope within the sequence of the respective ORF.and Meulenberg, 2001). The antigenicity of the gp2 is largely
unexplored, and there are no data available regarding the North
American strains. In this study, two B-cell linear epitopes were
found to be immunoreactive with 60% (9/15) of the sera (Fig. 5).
The reactive peptides comprise regions at amino acid positions
41–55 and 121–135 within the ORF2 sequence (Table 1). Using
phage-displayed peptides, Oleksiewicz et al. (2002) identifiedand structural proteins of PRRSV. The locations within the respective ORFs and
protein are indicated. See Table 1 for the amino acid position of each identified
Fig. 2. Seroconversion kinetics of 15 experimentally infected pigs against PRRSV-specific B-cell epitopes identified on Nsp2 (A) and structural proteins (B) of a North
American strain. Serum samples collected at 0, 7, 15, 30, 45 and 60 dpi were examined by peptide ELISA against all the immunodominant epitopes identified.
413M. de Lima et al. / Virology 353 (2006) 410–421three weakly antigenic B-cell epitopes in the ORF2 at positions
36–51, 117–139 and 120–142 of an EU-type strain. Although
the epitope mapping experiments were carried out using distinct
approaches and different strains, the amino acid sequence G-
123QAAWKQVVXEAT135 localized in the predicted most
hydrophilic domain of gp2 was identified in our study (peptide
#110) as well as in that by Oleksiewicz et al. (2002). Thus, those
residues might constitute the core of an epitope recognized by
sera from pigs infected with EU- and US-type of PRRSV.
However, it is important to consider that this region was
recognized only by 1 out of 6 sera tested by Oleksiewicz et al.(2002) and by 60% of the 15 sera tested in our study, indicating a
lesser immunodominance and diagnostic usefulness.
B-cell linear epitopes in the ORF3 protein
The highly glycosylated ORF3-encoded protein is the
second most variable PRRSV protein, showing approximately
54 to 60% aa identity between the North American and
European genotypes (Dea et al., 2000). In our investigation,
four overlapping consecutive peptides (pep #129–132) were
strongly immunoreactive with 85–100% of the tested sera
Fig. 3. Mean optical density (OD) scored by ELISA test using synthetic peptides recognized by the majority of the sera at 0 (open bars) and 60 dpi (darkened bars). The
two decimal values located above the bars indicate the standard deviations of the seropositive samples, while the number in parentheses correspond to the number of
reactive sera with each peptide (total of 15 sera examined). Peptides #3 to 81 (Nsp2); #102 and 110 (ORF2); #129 to 132 (ORF3); #184 (ORF5); #200 and 201 (ORF6)
and # 203 (ORF7). Refer to Table 1 for exact location of the peptides.
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amino acids 61–105, which is predicted to be located in the
most hydrophilic region within the ORF3 sequence. These data
suggest that this region might be considered as one important
immunodominant domain of the gp3 of North American strains
of PRRSV. Our findings are supported by results of a recent
analysis of the antigenic structure of gp3 encoded by a Chinese
isolate (US-type) of PRRSV (Zhou et al., 2005). After
sequential deletion of amino acid residues from each peptide,
these authors found that the minimal epitopes recognized by the
MAbs were located at residues Y67EPGRSLW74 and W-
74CRIGHDRCGED85. Interestingly, except for a serine instead
of a glycine at position 83, identical sequences recognized by
MAbs were found in the peptides #129 and #130 which were
reactive with 86.7 (13/15) and 93.3% (14/15) of the swine sera
examined in our study. Most importantly, a high degree of
sequence conservation within a segment comprising residues
69–78 and 90–99 was observed among North American
isolates and reference strains of PRRSV (Fig. 6). Furthermore,
in spite of the sequence variability observed among North
American and European strains in this segment of gp3,
Oleksiewicz et al. (2002) observed strong reactivity within a
region comprising the amino acids 60–87 of an EU-type isolate
of PRRSV.
B-cell linear epitopes in the ORF4 protein
The glycoprotein 4 (gp4) is a typical class I membrane
protein, and it is a minor constituent of the viral envelope
(Meulenberg, 2000). In the present study, only a small fraction(33.3% and 26.6%) of the tested sera were found to be reactive
with peptides #153 and #158 comprising amino acid residues
51–65 and 101–115 within the ORF4 protein (Fig. 5). The core
of a neutralization domain of the glycoprotein encoded by
ORF4 of Lelystad virus and recognized by MAbs consists of
amino acids 59 to 67 and is located at the most variable region
of the protein (Meulenberg et al., 1997). However, further
studies are necessary to demonstrate whether the linear epitope
identified in our study (aa 51–65) is recognized by neutralizing
antibodies. In addition, a single linear epitope in gp4 (aa 59–71)
encoded by a European strain was found to be immunodomi-
nant in pigs, and a putative decoy function for this region has
been suggested (Oleksiewicz et al., 2001, 2005). However, we
did not detect immunodominant sequences in this region
(peptide #153) since it was recognized by only 5 out of 15
tested sera.
B-cell linear epitopes in the ORF5 protein
Glycoprotein 5 (gp5) is one of the major structural proteins
encoded by PRRSV and forms disulfide-linked heterodimers
with M protein in the viral envelope (Snijder and Meulenberg,
2001). Specific IgG antibodies to gp5 are detected at the end of
the first week after infection and at around 14 dpi to M protein
(Dea et al., 2000). A neutralizing epitope (epitope B) in the
ectodomain of gp5 has been previously described (Ostrowski et
al., 2002). The core sequence of this neutralizing epitope “B”
(H38, Q40, I42, Y43 and N44) is present in peptide #168 that was
found to be reactive with 8 out of 15 sera in our experiments.
However, since neutralizing activity was observed in all of the
Fig. 4. (A) B-cell linear epitopes on the Nsp2 amino acid sequence of a North American strain of PRRSV identified by Pepscan analysis. Black bars represent the
immunodominant epitopes identified. Sera were considered positive when the OD values were above the cutoff point (the mean OD of absorbance at 405 nm of the
negative sera plus 3 standard deviations). (B). Hydropathic profile of the protein which was generated by the ProtScale program (http://us.expasy.org) with window
size of 21 and using parameters defined previously (Hoop and Woods, 1981).
415M. de Lima et al. / Virology 353 (2006) 410–42115 sera samples used in our experiments (including the seven
sera which did not react with peptide #168, data not shown), one
might speculate that, besides epitope B, there may be other
neutralizing epitopes present on PRRSV that would contribute
to the total PRRSV-neutralizing activity in the serum. In
addition, the peptide comprising the residues 187–200 (pep
#184) located in the 3′ endodomain of the protein was
recognized by 13/15 of the examined sera. The aa sequence
P188LTR(V/T)SAEQW197 was also found to be reactive with
sera raised against an European PRRSV strain (Oleksiewicz etal., 2002). Surprisingly, peptide #184 exhibited the lowest value
of the mean optical densities obtained among all the
immunodominant epitopes identified (Fig. 3). Despite some
amino acid changes within this region and the low immuno-
genicity observed, this decapeptide is relatively well conserved
among North American strains (Fig. 6). Most importantly, this
peptide was recognized by the majority of the animals used in
our experiment. This inverse correlation between immunogeni-
city and level of sequence conservation has been previously
described (Oleksiewicz et al., 2001).
Fig. 5. (A) B-cell linear epitopes identified along the structural proteins (ORFs 2–7) of a North American strain of PRRSV by Pepscan analysis. The numbers of the corresponding peptides in each ORF are indicated. Sera
were considered positive when the OD values were above the cutoff point (the mean OD of absorbance at 405 nm of the negative sera plus 3 standard deviations). (B) Hydropathic profiles of the proteins which were
generated by the ProtScale program (http://us.expasy.org) with window size of 9 and using parameters defined previously (Hoop and Woods, 1981). The localization of the immunodominant epitopes is indicated.
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Fig. 6. Multiple alignment of ORFs 3, 5, 6 and 7 among North American- and European-type PRRSV isolates. The amino acid sequences of the immunodominant
epitopes identified in each ORF are underlined. Alignments of the amino acid sequences were made using ClustalW (Thompson et al., 1994), and then the results were
retrieved and analyzed by Bio-Edit sequence alignment editor v. 7.0.5.
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The nonglycosylated M protein (16–20 kDa) is the most
conserved structural protein of arteriviruses. Abundant mole-
cules of M protein are present in the virion associated with gp5,
and its N-terminal half presumably traverses the envelope
membrane three times (Dea et al., 2000; Snijder and Meulen-berg, 2001). The protein has only a short stretch of 10 to 18
residues exposed at the virion surface and a large endodomain
(Dea et al., 2000; Snijder and Meulenberg, 2001). In this study,
we demonstrated that peptides #200–201 constitute a unique
combination of sequence conservation and antigenicity (Figs. 5
and 6). These peptides were found to be reactive with 100% of
sera examined. These immunoreactive peptides are located
418 M. de Lima et al. / Virology 353 (2006) 410–421within the region at position 151–174 which corresponds to the
C-terminus end of the endodomain of M protein. Eventually, the
5 aa (A161VKQG165) could be considered the minimal sequence
recognized by antibodies since this segment corresponds to the
overlapping residues of peptides #200 and #201. Oleksiewicz et
al. (2002) also reported the identification of one phage-
displayed epitope localized in the large putative endodomain
of the M protein (aa 138–159) of a European-type strain. In
their experiment, this epitope was recognized by a reduced
number of sera collected very late in infection. In the present
study, the overlapping peptides were reactive with 100% of the
sera examined. The identified epitopes were found to be highly
immunogenic and conserved among isolates and reference
strains of both PRRSV genotypes (Fig. 6). In order to confirm
the results demonstrated by the sequence alignment, we further
tested the reactivity of both synthetic peptides with sera from 21
pigs experimentally infected with the homologous (NVSL 97-
7895) PRRSV strain and antisera raised against four hetero-
logous US strains. As expected, all sera samples were confirmed
positive (data not shown). Reactivity of these two synthetic
peptides with a sizable number of field sera was also observed
(data not shown). In addition, antiserum against Lelystad virus
(European prototype strain of PRRSV) was also reactive with
peptide #201. These results demonstrate that the peptide
containing the residues A161VKQGVVNLVKYAK174 can be
particularly useful for diagnostic purposes and one attractive
candidate to be evaluated as a negative serological marker in a
PRRSV vaccine derived from infectious cDNA clones, if
proved to be dispensable from the ORF6 without affecting the
viability of the vaccine strain and/or protective immunity
induced by it.
B-cell epitopes in the ORF7 protein
After infection, most PRRSV-specific IgG antibodies are
primarily directed against the nucleocapsid (N) protein and are
detectable as early as 7 dpi. Thus, these antibodies may be useful
for diagnostic purposes (Dea et al., 2000). A commonly used
commercial PRRSV ELISA kit contains N protein as the single
antigen for serological diagnosis of PRRSV infections. Our
epitope mapping has demonstrated that, among the 12 peptides
derived from the N protein amino acid sequence, six were found
to be immunoreactive. Two out of these six peptides (pep #203,
aa 11–25 and #206, aa 41–55) located at predicted hydrophilic
domains of the protein were reactive with 14/15 and 7/15 of the
sera, respectively (Fig. 5). Furthermore, we observed that
residues G18(N/D)GQPVNQ25 contained in peptide #203,
which was recognized by 93.3% of the animals, were well
conserved among 33 isolates and reference strains from both
PRRSV genotypes (Fig. 6). Recently, An et al. (2005) using a
phage-displayed peptide library, identified a well conserved B-
cell epitope with an anti-N protein MAb. The core sequence
recognized by this MAb comprised the residues I79QTAF-
NQGA87 in the context of the N protein. No reactivity was
observed within that region probably because no peptide exam-
ined in our study contained the minimal sequence previously
identified as a B-cell epitope.Antibodies recognizing the immunodominant epitopes of Nsp2
and structural proteins appear between day 7 and 15 pi and
remain detectable until at least 90 dpi
Serum samples collected at different time points after
experimental infection were used to study the seroconversion
kinetics to the immunodominant epitopes identified in Nsp2 and
structural proteins of the NVSL 97-7895 strain. Animals
seroconverted to the immunogenic B-cell epitopes at different
times post-infection ranging from 7 to 45 dpi. Seroconversion
kinetics revealed that peptide-specific antibodies started
appearing generally between days 7 and 15 post-infection,
increased in titer with time and remained at fairly steady and
high levels up to day 60 pi (Fig. 2). In addition, reactivity was
also detected against all the identified epitopes with sera
collected at 90 dpi, although a slight decrease in the OD values
could be observed when compared to those recorded at 60 dpi
(not shown). Furthermore, the antibody response to some Nsp2
epitopes seemed to appear slightly earlier in some animals when
compared to the response against the structural proteins. How-
ever, the seroconversion kinetics to the immunodominant epi-
topes was not able to discriminate between the serological
response to Nsp2 and structural proteins.
Significance of the epitope information
The feasibility of a new strategy for designing marker
vaccines based on the deletion of immunodominant epitopes
has been recently demonstrated for RNA viruses (Castillo-
Olivares et al., 2003; Mebatsion et al., 2002). However, the
possibility of using such approach for the development of
PRRSV vaccines remains to be explored yet. Likewise,
information regarding immunogenicity and presence of B-cell
epitopes, which could be used as serological marker candidates,
in different US-type PRRSV proteins is scarce. Fang et al.
(2004) identified natural deletions within Nsp2 gene of
European-like PRRSV isolated in the United States, suggesting
that this protein could represent an ideal target for the
development of marker vaccines. The data presented in our
paper indicate the presence of several B-cell epitopes distributed
along the amino acid sequences of Nsp2 and structural proteins
of the North American strain NVSL 97-7895, which served as
basis for the construction of an infectious full-length cDNA
clone of PRRSV (Truong et al., 2004). Additionally, several
epitopes (especially those found in ORF6) were found to be
highly immunogenic, consistently recognized by the 15
PRRSV-infected pigs and well conserved among North
American and European strains of PRRSV. To our knowledge,
this is the first report demonstrating the presence of B-cell linear
epitopes consistently recognized by immune serum from pigs
experimentally infected with US-type PRRSV.
The detailed and systematic methodology employed in this
study by using overlapping synthetic peptides enabled us to
identify a higher frequency of B-cell linear epitopes (mainly in
Nsp2) in comparison to previous findings reported for EU-type
PRRSV strains. The identification of conserved and antigenic
peptides corresponding to B-cell epitopes consistently
419M. de Lima et al. / Virology 353 (2006) 410–421recognized by PRRSV-infected animals may have major
practical significance by providing the molecular basis for
development of improved diagnostic tests as the identified
epitopes may be considered serological marker candidates for
differential (infection vs. vaccination) marker PRRSV vaccines
derived from infectious cDNA clones.
Finally, it must be born in mind that some of the
immunodominant B-cell epitopes we identified on the
PRRSV proteins may have a role in PRRSV-neutralizing
activity and therefore on PRRSV protective immunity. It will be
interesting to investigate if additional epitopes other than “B”
epitope on GP5 and perhaps in other glycoproteins and M
protein have a role in neutralization. Such quality, although
important for protection and vaccine design, could recommend
against their use as deletable serologic differential markers.
Materials and methods
Cells and virus
Infectious PRRSV virus (US-type) recovered from MARC-
145 cells transfected with in vitro produced transcripts of the
full-length cDNA clone (FL12) of PRRSV NVSL 97-7895
(Truong et al., 2004) was used for animal inoculation and
antiserum production. The cells were propagated in Dulbecco's
Modified Eagle's Medium (DMEM) containing 10% fetal
bovine serum (FBS) and antibiotics (100 units/ml of penicillin,
20 μg/ml of streptomycin and 20 μg/ml of kanamycin). These
cells were used for electroporation of RNA, viral infection and
growth and for virus titration.
Animal inoculation
Fifteen mixed-breed (Landrace×Large White) piglets aver-
aging 3 weeks of age were obtained from a PRRSV-free farm.
The animals were allocated in three BL-2 isolation rooms and
inoculated with a total dose of 105.0 TCID50/3 ml of PRRSV
FL12 by intranasal (1 ml in each nostril) and intramuscular
(1 ml) routes. The animals were clinically monitored on a
daily basis, and their rectal temperatures were recorded from
2 days pre-inoculation to day 15 post-infection (pi).
Sequential blood samples were collected from all animals at
days 0 (zero), 7, 15, 30, 45, 60 and 90 pi and tested for
PRRSV-specific antibodies by using a commercially available
ELISA kit (Idexx Labs, Inc).
Synthetic peptides
A set of 213 overlapping 15-mer synthetic peptides, which
overlapped each other by 5 aa, spanning the entire amino acid
sequence of the nonstructural protein Nsp2 (n = 97) and all
structural proteins (ORF2, n = 25; ORF3, n = 25; ORF4,
n = 17; ORF5, n = 20; ORF6, n = 17 and ORF7, n = 12) of the
North American strain of PRRSV (NVSL 97-7895), were used
individually in a peptide-based enzyme-linked immunosorbent
assay. Peptides were synthesized using Fmoc solid-phase
chemistry by Open Biosystems, Inc, Huntsville, AL.Peptide ELISA
Serum samples collected at day 60 pi from the 15 piglets
experimentally infected with FL-12 strain were used for
screening of the peptide-specific antibody response by
ELISA. Briefly, Immulon 2HB flat bottom microtiter 96
well plates (Thermo Electron, Milford, MA) were coated
with 100 μl of a peptide solution (10 μg/ml) in 0.1 M
carbonate buffer (pH 9.6) and incubated overnight at 4 °C.
After blocking with 250 μl of a 10 wt.% nonfat dry milk
solution for 4 h at room temperature on a plate shaker, the
plates were washed three times with PBS containing 0.1%
Tween 20 (PBST-20). Unbound reagents were further
removed by striking the plates repeatedly, bottom up, on a
stack of absorbent paper towel. Then, 100 μl of pig sera
(1:20) diluted in 5 wt.% nonfat dry milk in PBST-20 was
added per well and plates were incubated on the shaker for
1 h at room temperature. After washing five times with
PBST-20, each well received and was incubated with 100 μl
of the affinity purified antibody peroxidase labeled goat anti-
swine IgG (KPL, Gaithersburg, MD) diluted 1:2000 in
PBST-20 with 5 wt.% nonfat dry milk for 30 min at room
temperature. Following a final wash, 100 μl of ABTS (KPL)
peroxidase substrate was added for 15 min at 37 °C and the
reaction was stopped by adding 100 μl of SDS 1%. A 12-
mer synthetic peptide (YKNTHLDLIYNA) which has been
shown to be recognized by PRRSV neutralizing antibodies
(Ostrowski et al., 2002) served as a positive peptide control.
Serum samples collected at day 0 (zero) were used as
negative control. Serum was considered positive when the
OD value was above the cutoff point (the mean OD
absorbance at 405 nm of the negative sera plus 3 standard
deviations). The same experimental conditions were applied
to ELISAs conducted with each one of the 213 synthetic
peptides used in this study.
Seroconversion kinetics
The seroconversion kinetics to the immunonodominat
epitopes identified in Nsp2, gp3 (ORF3), gp5 (ORF5), M
protein (ORF6) and N protein (ORF7) was examined by
using sequential serum samples collected from the infected
piglets at days 0, 7, 15, 30, 45 and 60 dpi in the
corresponding peptide-based ELISA. The serum was con-
sidered positive when the OD value was above the cutoff
point.
Bioinformatics analysis
Hydropathic profiles were produced by the ProtScale
program (http://us.expasy.org) using parameters defined pre-
viously (Hoop and Woods, 1981). Window sizes of 9 and 21
were used for all the structural proteins and for Nsp2,
respectively. Multiple alignments of amino acid sequences
were made using ClustalW (Thompson et al., 1994). Align-
ments were retrieved and analyzed by Bio-Edit sequence
alignment editor v. 7.0.5.
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